preclamol has been researched along with Idiopathic Parkinson Disease in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (75.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Antonio, T; Das, B; Dutta, AK; Luo, D; Reith, ME; Vedachalam, S | 1 |
Bravi, D; Chase, TN; Hoff, JI; Metman, LV; Mouradian, MM; Roberts, JR; Sethy, VH | 1 |
Carlsson, A; Merello, M; Pirtosek, Z; Stern, G | 2 |
1 review(s) available for preclamol and Idiopathic Parkinson Disease
Article | Year |
---|---|
Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Parkinson Disease; Piperidines | 1996 |
2 trial(s) available for preclamol and Idiopathic Parkinson Disease
Article | Year |
---|---|
Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Piperidines | 1994 |
Preclamol and parkinsonian fluctuations.
Topics: Antiparkinson Agents; Apomorphine; Blood Pressure; Dopamine Agonists; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Movement; Parkinson Disease; Piperidines; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
1 other study(ies) available for preclamol and Idiopathic Parkinson Disease
Article | Year |
---|---|
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Cell Line; Drug Discovery; Female; Humans; Locomotion; Male; Neuroprotective Agents; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Structure-Activity Relationship | 2015 |